The letter came in June. Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. What? she remembers thinking.

Up to a third of the weight lost while taking weight loss jabs such as Wegovy and Mounjaro includes muscle and bone mass.

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with obesity-related conditions or take the drugs to become eligible for other services,

Quartz spoke with Noom CEO Geoff Cook to get his take on what 2025 holds for the compounded drug market and the overall future of weight-loss drugs. Cook took over as CEO of the psychology-based weight loss app Noom in 2023,

People struggling with their body weight experienced joy when new, more effective prescription drug options became the rage in 2023, but it seems many folks stopped taking them in 2024.

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down double digits in premarket trading. CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid,

Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ability to maintain its lead in the exploding weight-loss market.

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug.

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and Wegovy, posted disappointing clinical trial data for its experimental obesity drug CagriSema.